InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,827.20
(
0.94%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,436.81
(
-0.37%
)
Post# of 252493
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119982
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 10/24/2022 10:46:57 AM

Monday, October 24, 2022 10:46:57 AM

Post# of 252493
AZN—FDA approves Imjudo (tremelimumab) for HCC:

https://finance.yahoo.com/news/imjudo-tremelimumab-combination-imfinzi-durvalumab-111200117.html

The approval was a long time coming!

Imjudo is a CTLA-4 inhibitor—the same MoA as BMY’s Yervoy. The FDA approval is for a combination regimen consisting of a single dose of Imjudo followed by monthly doses of Imfinzi (AZN’s PD-L1 inhibitor). This regimen was worked out after considerable trial and error by AZN.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up